Guizhou Yibai Pharmaceutical Co. Ltd. Class A

Guizhou Yibai Pharmaceutical Co. Ltd. Class A

SSSE:600594
3.04
CNY
-0.06
(-1.94%)
-0.50EPS
2.86BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Guizhou Yibai Pharmaceutical Co. Ltd. Class A carries a market capitalization of 2.86B, placing it among publicly traded companies globally. Its enterprise value stands at 3.21B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.86B
Enterprise Value3.21B

Share Statistics

As of September 30, 2026, Guizhou Yibai Pharmaceutical Co. Ltd. Class A has 784.39M shares outstanding.

Shares Outstanding784.39M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 2.03, and the price-to-book ratio stands at 1.40.

PS Ratio2.03
PB Ratio1.40
P/TBV Ratio1.65

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 2.28 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 3.21B versus a market cap of 2.86B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.28

Financial Position

As of September 30, 2026, Guizhou Yibai Pharmaceutical Co. Ltd. Class A maintains a current ratio of 1.54, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 31.80, indicating elevated leverage, while an interest coverage ratio of -15.60 demonstrates limited ability to service its debt obligations.

Current Ratio1.54
Quick Ratio0.49
Debt / Equity31.80
Debt / EBITDA-1.89
Interest Coverage-15.60

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Guizhou Yibai Pharmaceutical Co. Ltd. Class A posted a negative return on equity (ROE) of -17.50, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -10.93, reflecting losses generated across the asset base. The company generates approximately 291,017.46 in revenue per employee across its workforce of 4,832.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.18 indicates how many times Guizhou Yibai Pharmaceutical Co. Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-17.50
Return on Assets (ROA)-10.93
Revenue Per Employee291,017.46
Employee Count4,832.00
Inventory Turnover1.18

Taxes

CNY

Over the twelve months ended September 30, 2026, Guizhou Yibai Pharmaceutical Co. Ltd. Class A recorded 32.78M in income tax expense. The company reported a pretax loss of -360.17M and -394.25M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax32.78M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Guizhou Yibai Pharmaceutical Co. Ltd. Class A's stock has declined approximately 32.29% over the past 52 weeks. The 50-day moving average sits at 3.47, while the 200-day moving average is 3.75.

52-Week Price Change-32.29%
50-Day Moving Average3.47
200-Day Moving Average3.75

Income Statement

CNY

Over the twelve months ended September 30, 2026, Guizhou Yibai Pharmaceutical Co. Ltd. Class A generated 1.41B in revenue and converted that into -394.25M in net income, yielding earnings per share of -0.50. EBITDA reached -356.20M, while operating income came in at -159.58M.

Revenue1.41B
Gross Profit775.57M
Operating Income-159.58M
Pretax Income-360.17M
Net Income-394.25M
EBITDA-356.20M
EBIT-356.20M
Earnings Per Share (EPS)-0.50

Balance Sheet

CNY

As of September 30, 2026, Guizhou Yibai Pharmaceutical Co. Ltd. Class A holds 402.69M in cash and equivalents against 673.01M in total debt, resulting in a net debt position of 91.89M. Total book value stands at 2.04B, with working capital of 445.43M providing operational flexibility.

Cash & Cash Equivalents402.69M
Total Debt673.01M
Net Debt91.89M
Equity (Book Value)2.04B
Book Value Per Share2.60
Working Capital445.43M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-32.70M

Margins

Over the twelve months ended September 30, 2026, Guizhou Yibai Pharmaceutical Co. Ltd. Class A posted a gross margin of 55.15, reflecting its pricing power and cost economics. The operating margin of -11.35 and net profit margin of -28.04 provide insight into operational efficiency.

Gross Margin55.15
Operating Margin-11.35
Pretax Margin-25.61
Profit Margin-28.04
EBITDA Margin-25.33

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Guizhou Yibai Pharmaceutical Co. Ltd. Class A paid dividends of 0.04 per share. The dividend payout ratio of -7.19 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 9.87, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Guizhou Yibai Pharmaceutical Co. Ltd. Class A shareholders.

Dividend Per Share0.04
Payout Ratio-7.19
Shareholder Yield9.87

Stock Splits

Guizhou Yibai Pharmaceutical Co. Ltd. Class A's most recent stock split took place on July 16, 2015 with a 1:2 split ratio.

Last Split Date7/16/2015
Split Ratio1:2

Scores

As of September 30, 2026, Guizhou Yibai Pharmaceutical Co. Ltd. Class A has an Altman Z-Score of 2.27, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.27